Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Neurocrine Biosciences, Inc. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
NBIX · Nasdaq · Healthcare · Drug Manufacturers Specialty and Generic
$167.39-1.2%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 2, 2026